4//SEC Filing
DEKKERS MARIJN E 4
Accession 0001127602-24-018709
CIK 0001830214other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 4:22 PM ET
Size
9.0 KB
Accession
0001127602-24-018709
Insider Transaction Report
Form 4
DEKKERS MARIJN E
Director
Transactions
- Exercise/Conversion
Class A Common Stock
2024-06-12+105,263→ 386,480 total - Exercise/Conversion
Restricted Stock Units
2024-06-12−105,263→ 0 totalExercise: $0.00→ Class A Common Stock (105,263 underlying)
Holdings
- 5,515,364(indirect: By Novalis LifeSciences Investments I, L.P.)
Class A Common Stock
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
- [F3]The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
- [F4]In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Documents
Issuer
Ginkgo Bioworks Holdings, Inc.
CIK 0001830214
Entity typeother
Related Parties
1- filerCIK 0001216068
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 4:22 PM ET
- Size
- 9.0 KB